You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-CD20 therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ublituximab
  • Fort Collins, Colorado
  • +1 more
May 26, 2023

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Active, not recruiting
  • COVID-19
  • +3 more
  • Convalescent Plasma
  • Rochester, Minnesota
    Mayo Clinic
Jul 15, 2022

Cladribine Therapy After Anti CD20 Therapy

Active, not recruiting
  • Multiple Sclerosis
  • Cladribine Oral Tablet
  • +2 more
  • Lugano, Ticino, Switzerland
    Neurocenter of Southern Switzerland, Ospedale Regionale di Lugan
Mar 22, 2022

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous

Completed
  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
  • intralesional rituximab
  • supplemental autologous serum
  • Milano, Italy
    Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Membranous Nephropathy Trial in Bergamo, Ranica (MOR202)

Recruiting
  • Membranous Nephropathy
  • Bergamo, BG, Italy
  • +1 more
Mar 4, 2022

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Relapsed/Refractory Large B-Cell Lymphoma Trial in Beijing, Hangzhou (Prizloncabtagene autoleucel)

Recruiting
  • Relapsed/Refractory Large B-Cell Lymphoma
  • Prizloncabtagene autoleucel
  • Beijing, China
  • +1 more
Mar 24, 2023

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Thrombotic Thrombocytopenic Purpura Trial (Caplacizumab, Corticosteroids, anti-CD20 antibody)

Not yet recruiting
  • Thrombotic Thrombocytopenic Purpura
  • (no location specified)
Aug 8, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Scottsdale, Arizona
  • +2 more
Jan 5, 2023

Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in New Brunswick (Atezolizumab 1200 MG in 20 ML

Active, not recruiting
  • Refractory Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Atezolizumab 1200 MG in 20 ML Injection
  • +2 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Sep 27, 2022

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Relapsed and/or Refractory B-cell Lymphoma Trial in Stanford, Baltimore, Houston (Cyclophosphamide, Fludarabine, KITE-363)

Recruiting
  • Relapsed and/or Refractory B-cell Lymphoma
  • Stanford, California
  • +2 more
Aug 16, 2022

B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Hangzhou (QN-019a, Rituximab, Cyclophosphamid)

Recruiting
  • B-cell Lymphoma
  • B-cell Acute Lymphoblastic Leukemia
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of Medical College of Zhejiang Uni
May 17, 2022

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension Trial in Beijing (Rituximab)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • Pulmonary Arterial Hypertension
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Apr 13, 2023

HBV Reactivation in Anti CD20 Treatment

Active, not recruiting
  • Hepatitis B
    • Afula, Tsafon, Israel
      HaEmek Medical Center
    Mar 14, 2023

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 18, 2022